Core Insights - Addex Therapeutics has made a strategic investment of CHF 2 million in Stalicla, a company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders [1][2] - The investment aims to support Stalicla's portfolio of autism-focused drug candidates and its series C financing, while also enhancing Addex's commitment to advancing innovative treatments for CNS disorders [2][3] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, with a lead drug candidate, dipraglurant, under evaluation for brain injury recovery [4] - Stalicla has raised over $50 million in equity and more than $30 million in non-dilutive funding, focusing on transforming treatments for neurodevelopmental disorders [3][4] Investment Details - The investment will enable Stalicla to advance its lead autism candidate STP1 and a second asset into Phase 2 trials, targeting specific subpopulations within autism spectrum disorder (ASD) [2][3] - Stalicla is also progressing its STP7 program (mavoglurant) for cocaine use disorders, which is the most advanced treatment candidate in development for this indication [2][3] Leadership Changes - As part of the investment, Addex CEO Tim Dyer has been appointed to Stalicla's Board of Directors and nominated as Chairman, indicating a deeper collaboration between the two companies [1][2]

Core Insights - Stalicla SA has successfully closed a CHF 2 million financing round led by Addex Therapeutics to advance its precision medicine programs for neurodevelopmental disorders [1][2] - The financing will support Stalicla's operations and program development as it prepares for a Series C financing and partnerships for key programs [1][2] - Stalicla's DEPI precision neuro platform and its autism assets, STP1 and STP2, have garnered investor confidence, while the STP7 program (mavoglurant) is progressing towards Phase 3 trials [1][3] Company Overview - Stalicla SA is a clinical-stage biopharmaceutical company based in Switzerland, having raised over $50 million in equity and more than $30 million in non-dilutive funding to enhance treatments for neurodevelopmental disorders [3] - The company has developed a neuro precision development platform that identifies stratified patient subgroups, facilitating personalized treatment options [3] - Stalicla is preparing to initiate Phase 2 trials for its leading asset, STP1, targeting specific subpopulations within autism, while STP7 is advancing towards Phase 3 trials with funding from the US government [3] Leadership and Strategic Direction - Tim Dyer has been appointed to the Board of Directors of Stalicla and nominated as Chairman, indicating a strategic partnership with Addex Therapeutics [2] - Lynn Durham, CEO of Stalicla, emphasized the importance of this financing in reaching significant milestones, including transformative clinical trials in autism and substance use disorders [2] - Addex Therapeutics recognizes Stalicla's platform as world-leading in precision medicine for neurodevelopmental disorders and aims to support the advancement of these critical medicines [2]